Andrzej Potemkowski
University of Szczecin
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrzej Potemkowski.
Medical Science Monitor | 2014
Barbara Nowacka; Wojciech Lubiński; Krystyna Honczarenko; Andrzej Potemkowski; Krzysztof Safranow
Background The aim of this study was to determine the type and frequency of ophthalmologic changes occurring in patients with Parkinson disease (PD). Material/Methods One hundred consecutive patients (196 eyes) with idiopathic PD and a control group consisting of 100 healthy patients (196 eyes) matched for age and sex underwent a complete ophthalmological examination of both eyes, including assessment of patient medical history, dry eye questionare, and visual hallucinations questionnaire, distance and near best corrected visual acuity (DBCVA, NBCVA), color vision, distance photopic contrast sensitivity, near point of convergence, slit lamp examination of the eye anterior segment, tear film osmolarity and breakup time, aqueous tear production, and intraocular pressure, as well as fundus examination and evaluation of the perimacular retinal thickness (RT) and peripapillary retinal nerve fiber layer (RNFL) thickness. Results In the eyes of PD patients DBCVA, NBCVA, contrast sensitivity, and color discrimination were significantly reduced. We also detected increased frequency of convergence insufficiency, seborrhoic blepharitis, meibomian gland disease (MGD), dry eye syndrome, nuclear and posterior subcapsular cataract, and glaucoma (p<0.05). However, intraocular pressure (IOP) was significantly lower in the PD group compared to controls. The frequency of visual hallucinations, age-related macular degeneration (ARMD), and other ophthalmological diseases, as well as RT and RNFL thickness, did not significantly differ between investigated groups. Conclusions Clinicians need to be aware of the association between PD and ophthalmological changes. Restoration of good-quality vision has a great impact on PD patients’ quality of life, reduction of costs of treatment and care, and rehabilitation.
Pharmacological Reports | 2012
Piotr Tybura; Agnieszka Samochowiec; Aleksander Beszlej; Anna Grzywacz; Monika Mak; Dorota Frydecka; Przemyslaw Bienkowski; Paweł Mierzejewski; Andrzej Potemkowski; Jerzy Samochowiec
BACKGROUND Therapeutic effects of all clinically used antipsychotics are related to the reduction of dopaminergic transmission in the limbic system. The aim of present study was two-fold. First, efficacy of atypical drugs (ziprasidone and olanzapine) against schizophrenia symptoms was compared to that offered by a typical antipsychotic medication, perazine. Second, associations between some dopaminergic genes polymorphisms and therapeutic response to antipsychotics were assessed in the same group of schizophrenia patients. METHODS One hundred ninety one Caucasian patients admitted with exacerbation of paranoid schizophrenia were genotyped for polymorphisms of the DRD2 [the ins/del -141C (rs1799732) and exon 8 (rs 71653615)], DRD2/ANKK1 Taq IA(rs 1800497), DAT1 (the 40 bp VNTR), COMT (rs 4680), and MAOA gene (the 30 bp VNTR in promoter). The patients were randomly assigned to the treatment with perazine, olanzapine or ziprasidone given as monotherapy for 3 months. Treatment efficacy was measured from baseline (T0) to T1 (14 days) and T2 (3 months). A retention rate was also assessed at T1 and T2. RESULTS The three antipsychotics did not differ in terms of reduction of the PANSS score or retention rate at the follow-up. There was no interaction between the investigated polymorphisms and response to the antipsychotic treatment. CONCLUSIONS The present results suggest that: i) there are no major differences in short-term efficacy or effectiveness of atypical (olanzapine, ziprasidone) and typical (perazine) antipsychotic drugs; ii) the studied polymorphisms are not primarily involved in treatment response to antipsychotics in schizophrenia patients.
Aktualności Neurologiczne | 2017
Waldemar Brola; Piotr Sobolewski; Stanisław Flaga; Małgorzata Fudala; Andrzej Potemkowski
© Medical Communications Sp. z o.o. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (CC BY-NC-ND). Reproduction is permitted for personal, educational, non-commercial use, provided that the original article is in whole, unmodified, and properly cited. Primary progressive multiple sclerosis in the Polish population Pierwotnie postępująca postać stwardnienia rozsianego w populacji polskich pacjentów
Documenta Ophthalmologica | 2010
Kamila Krasodomska; Wojciech Lubiński; Andrzej Potemkowski; Krystyna Honczarenko
Documenta Ophthalmologica | 2015
Barbara Nowacka; Wojciech Lubiński; Krystyna Honczarenko; Andrzej Potemkowski; Krzysztof Safranow
Psychiatria Polska | 2014
Tyburski E; Andrzej Potemkowski; Magdalena Chęć; Sołtys A; Monika Mak; Agnieszka Samochowiec
Postępy Psychiatrii i Neurologii | 2018
Ernest Tyburski; Monika Mak; Jacek Kurpisz; Agnieszka Samochowiec; Andrzej Potemkowski
Polski Przegląd Neurologiczny | 2017
Andrzej Potemkowski; Aleksandra Janac; Waldemar Brola
Aktualności Neurologiczne | 2017
Andrzej Potemkowski; Marta Wąsik; Marcin Ratajczak
Psychiatria Polska | 2016
Magdalena Chęć; Andrzej Potemkowski; Marta Wąsik; Agnieszka Samochowiec